Rheumatoid Arthritis
📧 Sign up to get email alerts when something new happens for Rheumatoid Arthritis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-12EMA Authorised: Xeljanz (tofacitinib) — Pfizer Europe MA EEIG
The EMA has authorised Xeljanz (tofacitinib) for rheumatoid arthritis, with Pfizer Europe MA EEIG as the marketing authorization holder.
-
EMA approval · 2025-12-19EMA Authorised: Leflunomide medac (leflunomide) — medac Gesellschaft für klinische Spezialpräparate mbH
The EMA authorised Leflunomide medac (leflunomide) for treatment of rheumatoid arthritis. The marketing authorization holder is medac Gesell…
-
EMA approval · 2025-12-18EMA Authorised: Leflunomide ratiopharm (leflunomide) — Ratiopharm GmbH
EMA authorised Leflunomide ratiopharm for rheumatoid arthritis; the product is manufactured by Ratiopharm GmbH.
-
EMA approval · 2025-12-16EMA Authorised: Erelzi (etanercept) — Sandoz GmbH
The EMA authorised Erelzi (etanercept) by Sandoz GmbH as a biosimilar to treat several inflammatory conditions including rheumatoid arthriti…
-
EMA approval · 2025-12-15EMA Authorised: Remicade (infliximab) — Janssen Cilag International NV
The EMA has authorised Remicade (infliximab) for multiple inflammatory diseases under Janssen Cilag International NV as the marketing author…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-12-11EMA Authorised: Hyrimoz (adalimumab) — Sandoz GmbH
EMA authorised Hyrimoz (adalimumab) by Sandoz GmbH as a biosimilar to Humira for multiple inflammatory diseases, including rheumatoid arthri…
-
FDA approval · 2025-12-10FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for ACTEMRA (tocilizumab) submitted by Genentech, Inc.
-
EMA approval · 2025-12-01EMA Authorised: Benepali (etanercept) — Samsung Bioepis NL B.V.
The European Medicines Agency authorised Benepali (etanercept), a biosimilar to etanercept, for inflammatory conditions including rheumatoid…
-
EMA approval · 2025-11-28EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
The European Medicines Agency authorised Rinvoq (upadacitinib) from AbbVie Deutschland GmbH & Co. KG for rheumatoid arthritis.
-
EMA approval · 2025-11-20EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
The EMA authorised Gobivaz (golimumab) for multiple inflammatory diseases. Indications include rheumatoid arthritis, juvenile idiopathic art…
-
EMA approval · 2025-11-10EMA Authorised: Flixabi (infliximab) — Samsung Bioepis NL B.V.
The EMA authorised Flixabi, a biosimilar of infliximab, for several inflammatory diseases. The indications include rheumatoid arthritis, pso…
-
FDA approval · 2025-11-04FDA Approved: SULFASALAZINE — Original Application (Rising Pharma Holdings, Inc.)
FDA approved the original ANDA for sulfazalasine (sulfasalazine) manufactured by Rising Pharma Holdings, Inc.
-
FDA approval · 2025-10-28FDA Approved: RENFLEXIS — Supplemental Application (Organon LLC)
FDA approved a supplemental application for RENFLEXIS (infliximab) submitted by Organon LLC. The approval updates the product labeling to re…
-
FDA approval · 2025-10-24FDA Approved: LEFLUNOMIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for Leflunomide filed by Chartwell RX, LLC under ANDA077086.
-
EMA approval · 2025-10-22EMA Authorised: Amsparity (adalimumab) — Pfizer Europe MA EEIG
EMA authorised Amsparity (adalimumab) from Pfizer Europe MA EEIG. The biosimilar is approved for multiple autoimmune indications including r…
-
EMA approval · 2025-10-21EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Idacio, a biosimilar of adalimumab, for multiple inflammatory diseases, produced by Fresenius Kabi Deutschland GmbH. The indi…
-
FDA approval · 2025-10-17FDA Approved: HADLIMA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for HADLIMA (adalimumab-bwwd) from Organon LLC, supporting expanded indications for this adalimumab …
-
EMA approval · 2025-10-17EMA Authorised: Arava (leflunomide) — Sanofi-aventis Deutschland GmbH
The European Medicines Agency authorised Arava (leflunomide) for the treatment of rheumatoid arthritis and psoriatic arthritis, with Sanofi-…
-
FDA approval · 2025-10-16FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ (tofacitinib) filed by Pfizer Laboratories Div Pfizer Inc, resulting in changes to t…
-
FDA approval · 2025-10-16FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
FDA approved a supplemental application for Amjevita (adalimumab-atto) submitted by Nuvaila Limited.
-
EMA approval · 2025-10-08EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Humira (adalimumab) by AbbVie Deutschland GmbH & Co. KG for multiple indications including ankylosing spondylitis, juveni…
-
EMA approval · 2025-10-06EMA Authorised: Rixathon (rituximab) — Sandoz GmbH
EMA authorised Rixathon (rituximab) by Sandoz as a biosimilar to Rituxan for several autoimmune and hematologic diseases, expanding access t…
-
FDA approval · 2025-10-03FDA Approved: NAPROXEN — Original Application (Aurobindo Pharma Limited)
FDA approved Naproxen from Aurobindo Pharma Limited as an original generic application (ANDA 216504). Naproxen is a nonsteroidal anti-inflam…
-
EMA approval · 2025-10-02EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Tyenne (tocilizumab) by Fresenius Kabi Deutschland GmbH for multiple indications, including rheumatoid arthritis, juvenile id…
-
EMA approval · 2025-09-29EMA Authorised: Truxima (rituximab) — Celltrion Healthcare Hungary Kft.
EMA authorised Truxima (rituximab) by Celltrion Healthcare Hungary Kft. as a biosimilar rituximab for several indications including Non-Hodg…